Evidence map›Paper›PMID 40659652›Full record

ArticleNPJ Parkinson's disease2025

REM density in Parkinson's disease: association with motor, cognitive, autonomic function, and dopaminergic medication.

Andrew Dagay, Shlomit Katzav, Noa Elisha, Jana Volkov, Riva Tauman, Nir Giladi, Jeffrey M Hausdorff, Anat Mirelman, Jennifer Zitser

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew DagaySagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Shlomit KatzavLaboratory for Early Markers of Neurodegeneration (LEMON), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Noa ElishaGray School of Medicine & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Jana VolkovLaboratory for Early Markers of Neurodegeneration (LEMON), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Riva TaumanSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Nir GiladiSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Jeffrey M HausdorffSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Anat Mirelman *Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel. anatmi@tlvmc.gov.il.
Jennifer Zitser *Sieratzki Sagol Institute for Sleep Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Funding

U.S. Department of Defense W81XWH2010468
6 · The paper itself

Abstract

Recent work has shown that REM density, defined as the number of rapid eye movements per REM sleep minute, is decreased in people with Parkinson's disease (PD) and is associated with greater bradykinesia, suggesting a motor component. This study explored the association of REM density with gait, cognitive function, and heart rate variability (HRV). Seventy-seven PD patients underwent overnight polysomnography. Gait was evaluated using wearable technology during preferred-speed walking and while walking with a cognitive task (dual tasking). Lower REM density was associated with poorer gait and mobility, particularly during dual-tasking and turning, but not with HRV. Patients taking evening slow-release dopaminergic medication showed higher REM density compared to drug-naïve patients or those on daytime medication. These findings highlight the role of motor and cognitive functions in the generation of rapid eye movements in PD. Administration of evening medications appears to improve REM density, likely by alleviating motor control deficits.

Identifiers

PMID40659652
PMCPMC12259987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.